Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1016/j.cell.2020.07.038
Licence creative commons licence
Title (Primary) IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression
Author Sadik, A.; Somarribas Patterson, L.F.; Öztürk, S.; Mohapatra, S.R.; Panitz, V.; Secker, P.F.; Pfänder, P.; Loth, S.; Salem, H.; Prentzell, M.T.; Berdel, B.; Iskar, M.; Faessler, E.; Reuter, F.; Kirst, I.; Kalter, V.; Foerster, K.I.; Jäger, E.; Ramallo Guevara, C.; Sobeh, M.; Hielscher, T.; Poschet, G.; Reinhardt, A.; Hassel, J.C.; Zapatka, M.; Hahn, U.; von Deimling, A.; Hopf, C.; Schlichting, R.; Escher, B.I.; Burhenne, J.; Haefeli, W.E.; Ishaque, N.; Böhme, A.; Schäuble, S.; Thedieck, K.; Trump, S.; Seiffert, M.; Opitz, C.A.
Source Titel Cell
Year 2020
Department OEC; UMB; ZELLTOX
Volume 182
Issue 5
Page From 1252
Page To 1270.e34
Language englisch
Keywords AHR; aryl hydrocarbon receptor; IL4I1; interleukin 4 induced 1; T cell exhaustion; tryptophan metabolism; tumor micro-environment; adaptive immunity; kynurenic acid CLL
Abstract Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The context specificity of AHR target genes has so far impeded systematic investigation of AHR activity and its upstream enzymes across human cancers. A pan-tissue AHR signature, derived by natural language processing, revealed that across 32 tumor entities, interleukin-4-induced-1 (IL4I1) associates more frequently with AHR activity than IDO1 or TDO2, hitherto recognized as the main Trp-catabolic enzymes. IL4I1 activates the AHR through the generation of indole metabolites and kynurenic acid. It associates with reduced survival in glioma patients, promotes cancer cell motility, and suppresses adaptive immunity, thereby enhancing the progression of chronic lymphocytic leukemia (CLL) in mice. Immune checkpoint blockade (ICB) induces IDO1 and IL4I1. As IDO1 inhibitors do not block IL4I1, IL4I1 may explain the failure of clinical studies combining ICB with IDO1 inhibition. Taken together, IL4I1 blockade opens new avenues for cancer therapy.
Persistent UFZ Identifier https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=23546
Sadik, A., Somarribas Patterson, L.F., Öztürk, S., Mohapatra, S.R., Panitz, V., Secker, P.F., Pfänder, P., Loth, S., Salem, H., Prentzell, M.T., Berdel, B., Iskar, M., Faessler, E., Reuter, F., Kirst, I., Kalter, V., Foerster, K.I., Jäger, E., Ramallo Guevara, C., Sobeh, M., Hielscher, T., Poschet, G., Reinhardt, A., Hassel, J.C., Zapatka, M., Hahn, U., von Deimling, A., Hopf, C., Schlichting, R., Escher, B.I., Burhenne, J., Haefeli, W.E., Ishaque, N., Böhme, A., Schäuble, S., Thedieck, K., Trump, S., Seiffert, M., Opitz, C.A. (2020):
IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression
Cell 182 (5), 1252 - 1270.e34 10.1016/j.cell.2020.07.038